Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Coya Therapeutics, Inc. and keeping the price target at $18.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju’s rating is based on several promising developments and potential catalysts for Coya Therapeutics. The company has recently submitted additional non-clinical data to the FDA, which supports the initiation of the COYA 302 Phase 2 trial for ALS patients. This submission is expected to lead to a decision on the Investigational New Drug application soon, which could trigger milestone payments from their strategic partner, Dr. Reddy’s Laboratories. Additionally, upcoming publications and data releases related to their research in neurodegenerative diseases like Parkinson’s and Alzheimer’s further bolster the company’s potential.
Financially, Coya Therapeutics ended the second quarter of 2025 with a solid cash position, which, combined with anticipated milestone payments, should sustain operations into the second half of 2026. The valuation of Coya is supported by a discounted cash flow analysis, which projects a price target of $18 per share. However, Selvaraju acknowledges risks such as clinical setbacks, regulatory challenges, and partnership uncertainties, but the overall outlook remains positive, justifying the Buy rating.
According to TipRanks, Selvaraju is a top 100 analyst with an average return of 26.3% and a 57.26% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Cognition Therapeutics, and Axsome Therapeutics.